BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Prognosis
971 results:

  • 1. [colorectal adenocarcinoma with enteroblastic differentiation: a clinicopathological analysis of eight cases].
    Wang Q; Zhang Y; Tan C; Ni SJ; Huang D; Chang B; Sheng WQ; Wang L
    Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):370-376. PubMed ID: 38556821
    [No Abstract]    [Full Text] [Related]  

  • 2. Concurrent kras p.G12C mutation and ANK3::RET fusion in a patient with metastatic colorectal cancer: a case report.
    Bedau T; Heydt C; Siebolts U; Zander T; Kraemer M; Loeser H; Buettner R; Quaas A
    Diagn Pathol; 2024 Mar; 19(1):55. PubMed ID: 38539256
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Impact of kras mutation on the tumor microenvironment in colorectal cancer.
    Zhou Y; Kuang Y; Wang C; Yu Y; Pan L; Hu X
    Int J Biol Sci; 2024; 20(5):1947-1964. PubMed ID: 38481800
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Negative prognostic impact of Co-mutations in TGFβ and TP53 pathways in surgically resected rectal tumors following neoadjuvant chemoradiotherapy.
    Qian C; Yang W; Li M; Feng Y; Dai N; Luo H; Jian D; Li X; Yang Y; He Y; Wang D; Li C; Xiao H
    Eur J Surg Oncol; 2024 Apr; 50(4):108242. PubMed ID: 38460248
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. HER2 expression and genOmic characterization of rESected brain metastases from colorectal cancer: the HEROES study.
    Prete AA; Angerilli V; Bergamo F; Vettore V; De Toni C; Intini R; Cerma K; Ricagno G; Cerantola R; Perissinotto E; De Rosa A; Ceccon C; Gasparello J; Denaro L; D'Amico A; Chioffi F; Carcea E; Fassan M; Lonardi S
    Br J Cancer; 2024 May; 130(8):1316-1323. PubMed ID: 38347094
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Primary vulvar adenocarcinoma of intestinal type: Report of two cases showing molecular similarity with colorectal adenocarcinoma.
    Mateoiu C; Palicelli A; Maloberti T; De Biase D; De Leo A; Lindh M; Bohlin KS; Stolnicu S
    Pathol Res Pract; 2024 Mar; 255():155181. PubMed ID: 38340583
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Genetic specificity study using next-generation sequencing (NGS) of peritoneal metastatic colorectal cancer compared to primary colorectal cancer.
    Lee S; Shin W; Park DG; Namgung H
    Genes Genomics; 2024 Mar; 46(3):289-302. PubMed ID: 38316717
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Integrating cfDNA liquid biopsy and organoid-based drug screening reveals PI3K signaling as a promising therapeutic target in colorectal cancer.
    Yang H; Xiao X; Zeng L; Zeng H; Zheng Y; Wang J; Li G; Dai W; He Y; Wang S; Peng J; Chen W
    J Transl Med; 2024 Feb; 22(1):132. PubMed ID: 38310289
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Genetic Polymorphisms and Tumoral Mutational Profiles over Survival in Advanced colorectal cancer Patients: An Exploratory Study.
    Cayún JP; Cerpa LC; Colombo A; Cáceres DD; Leal JL; Reyes F; Gutiérrez-Cáceres C; Calfunao S; Varela NM; Quiñones LA
    Curr Oncol; 2024 Jan; 31(1):274-295. PubMed ID: 38248103
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Clinicopathological and molecular characteristics of colorectal adenosquamous carcinoma in an Asian population.
    Ye F; Chen M; Zheng X; Huang P; Wang C; Liu H; Xie H; Xiao W; Guo Q; Huang L
    BMC Gastroenterol; 2024 Jan; 24(1):36. PubMed ID: 38229035
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Nuclear pore protein POM121 regulates subcellular localization and transcriptional activity of PPARγ.
    Yu Y; Farooq MS; Eberhart Meessen S; Jiang Y; Kato D; Zhan T; Weiss C; Seger R; Kang W; Zhang X; Yu J; Ebert MPA; Burgermeister E
    Cell Death Dis; 2024 Jan; 15(1):7. PubMed ID: 38177114
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. colorectal Carcinoma With Sarcomatoid Components: Report of 15 Cases and Literature Review of an Exceedingly Rare Carcinoma Subtype.
    Golconda U; McHugh KE; Allende DS; Collins K; Henn P; Lacambra M; Bejarano PA; Groisman GM; Loughrey MB; Monappa V; Zhang X; Hornick JL; Gonzalez RS
    Am J Surg Pathol; 2024 Apr; 48(4):465-474. PubMed ID: 38155543
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Targeted Mass Spectrometry Analyses of Somatic Mutations in colorectal cancer Specimens Using Differential Ion Mobility.
    Wu Z; Bonneil É; Belford M; Boeser C; Dunyach JJ; Thibault P
    J Proteome Res; 2024 Feb; 23(2):644-652. PubMed ID: 38153093
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Site specific genetic differences in colorectal cancer via Next-Generation-Sequencing using a multigene panel.
    Rencuzogullari A; Bisgin A; Erdogan KE; Gumus S; Yalav O; Boga I; Sonmezler O; Eray IC
    Ann Ital Chir; 2023; 94():605-611. PubMed ID: 38131395
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Regorafenib therapy as a third-line treatment for metastatic colorectal cancer: A single center long term experience.
    Ozkan M; Oflazoglu U; Yildiz Y; Güc ZG; Salman T; Ünal S; Kücükzeybek Y; Alacacioglu A
    Medicine (Baltimore); 2023 Dec; 102(50):e36435. PubMed ID: 38115370
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. KLK10 promotes the progression of kras mutant colorectal cancer via PAR1-PDK1-AKT signaling pathway.
    Wu K; Wu B; Yan K; Ding Q; Miao Z
    Cell Biol Int; 2024 Apr; 48(4):440-449. PubMed ID: 38115179
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Leveraging a kras-based signature to predict the prognosis and drug sensitivity of colon cancer and identifying SPINK4 as a new biomarker.
    Huo JT; Tuersun A; Yu SY; Zhang YC; Feng WQ; Xu ZQ; Zhao JK; Zong YP; Lu AG
    Sci Rep; 2023 Dec; 13(1):22230. PubMed ID: 38097680
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. kras status predicted by pretreatment MRI radiomics was associated with lung metastasis in locally advanced rectal cancer patients.
    Xiang Y; Li S; Song M; Wang H; Hu K; Wang F; Wang Z; Niu Z; Liu J; Cai Y; Li Y; Zhu X; Geng J; Zhang Y; Teng H; Wang W
    BMC Med Imaging; 2023 Dec; 23(1):210. PubMed ID: 38087207
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high colorectal cancer after Treatment Termination.
    Simmons K; Thomas JV; Ludford K; Willis JA; Higbie VS; Raghav KPS; Johnson B; Dasari A; Kee BK; Parseghian CM; Lee MS; Le PH; Morelli MP; Shen JP; Bent A; Vilar E; Wolff RA; Kopetz S; Overman MJ; Morris VK
    Cancer Res Commun; 2023 Dec; 3(12):2510-2517. PubMed ID: 38085001
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations.
    Chen J; Chang X; Li X; Liu J; Wang N; Wu Y; Zheng L; Nie X
    Cancer Med; 2023 Dec; 12(24):21920-21932. PubMed ID: 38063316
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 49.